8月30日，知名药企绿叶制药（02186）发布截至2026年6月30日止六个月的中期业绩公告。公告显示，上半年公司收入为30.02亿元，同比减少1.79亿元或5.6%；毛利减少至19.02亿元，毛利率为63.4%，同比下降11.8%；净利润为3.81亿元，同比增长6.5%；股东应占溢利为3.91亿元，增长24.8%。 从业务板块来看，代表高毛利新药方向的中枢神经系统（CNS）板块收入持续稳健上行...
Source Link8月30日，知名药企绿叶制药（02186）发布截至2026年6月30日止六个月的中期业绩公告。公告显示，上半年公司收入为30.02亿元，同比减少1.79亿元或5.6%；毛利减少至19.02亿元，毛利率为63.4%，同比下降11.8%；净利润为3.81亿元，同比增长6.5%；股东应占溢利为3.91亿元，增长24.8%。 从业务板块来看，代表高毛利新药方向的中枢神经系统（CNS）板块收入持续稳健上行...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.